Industry focused on innovation, resilience, and collaboration to support growth
Aug 6, 2026 (ARLINGTON, VA)– The single-use bioprocessing industry is operating in a more normalized post-pandemic environment, with companies focused on growth, innovation, emerging technologies, automation and artificial intelligence, manufacturing flexibility, and the role single-use technologies will play as new modalities-including cell therapies, gene therapies, and other advanced biopharmaceutical therapies-continue to mature.
Those priorities shaped discussions at the 2026 BPSA International Single-Use Summit, held July 27–29 at the Fairmont Copley Plaza in Boston, MA, USA. Hosted by the Bio-Process Systems Alliance (BPSA), the international association representing the single-use bioprocessing industry, the Summit brought together suppliers, end users, pharmaceutical and biotechnology professionals, and key industry partners. This year marked the first time BPSA brought the Summit to Boston, where the event drew record attendance and connected the global single-use community with one of the world’s leading regions for biopharmaceutical innovation and manufacturing. The strong turnout also reflected BPSA’s continued member engagement and momentum following the association’s 20th anniversary in 2025.
The conversations come at a pivotal time for the industry. Several major market research firms point to continued strong growth in the global single-use bioprocessing market over the next decade. While exact projections vary, many expect the market to roughly double, driven by rising demand for biologics, vaccines, cell therapies, gene therapies, and other advanced modalities.
“BPSA’s Summit has always been where BPSA members and the single-use community come together to discuss the issues that matter most to our industry,” said Chris Clark, Executive Director of BPSA. “Single-use technologies now sit at the center of modern biopharmaceutical manufacturing. What we heard in Boston is that the industry is using these technologies strategically to improve efficiency, support enabling technologies, strengthen quality, and advance innovation. Ultimately, this work supports a larger goal: helping ensure that critical therapies continue reaching patients and consumers around the world,” Clark added.
BPSA extends its appreciation to the 2026 Summit co-chairs, David Radspinner of VintaBio and Brendan Lucey of Kivi Bio, for helping shape this year’s program. BPSA also recognizes Bürkert Fluid Control Systems as the exclusive Welcome Reception Sponsor and thanks its sustaining sponsors, including AdvantaPure, Bürkert Fluid Control Systems, CPC Biotech, Cytiva, Entegris, MilliporeSigma, PendoTECH, RENOLIT Healthcare Solutions, Saint-Gobain, Sartorius, and Solvias, for their ongoing support.
BPSA membership is open to organizations of every size across the single-use value chain-component and material suppliers, equipment manufacturers, pharmaceutical manufacturers, CDMOs, testing and service providers, and other biotechnology companies. Members help shape the industry’s technical guidance and standards, gain early access to BPSA working groups and publications, and connect directly with the end users specifying single-use systems.
About BPSA
Bio-Process Systems Alliance (BPSA) is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, and networking opportunities among its member companies.
